Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $130.1 million.

  • Arrowhead Pharmaceuticals' Accumulated Expenses rose 11898.79% to $130.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $130.1 million, marking a year-over-year increase of 11898.79%. This contributed to the annual value of $90.4 million for FY2025, which is 4348.35% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Accumulated Expenses of $130.1 million as of Q4 2025, which was up 11898.79% from $90.4 million recorded in Q3 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Accumulated Expenses peaked at $130.1 million during Q4 2025, and registered a low of $12.9 million during Q1 2021.
  • Its 5-year average for Accumulated Expenses is $48.1 million, with a median of $43.2 million in 2023.
  • In the last 5 years, Arrowhead Pharmaceuticals' Accumulated Expenses surged by 23466.18% in 2022 and then crashed by 1513.79% in 2023.
  • Arrowhead Pharmaceuticals' Accumulated Expenses (Quarter) stood at $18.5 million in 2021, then soared by 160.15% to $48.2 million in 2022, then decreased by 3.26% to $46.6 million in 2023, then grew by 27.46% to $59.4 million in 2024, then soared by 118.99% to $130.1 million in 2025.
  • Its last three reported values are $130.1 million in Q4 2025, $90.4 million for Q3 2025, and $64.8 million during Q2 2025.